ABBV AbbVie Inc.

AbbVie Inc. (ABBV) is a cash-generative pharma franchise — Skyrizi and Rinvoq now the growth engines past the Humira patent cliff, plus aesthetics (Botox/Juvederm) and neuroscience. FY2025 10-K via SEC XBRL: revenue $61.16B (+12.4% YoY), operating income $15.08B (~25% reported op margin; EODHD TTM op margin 32%), operating cash flow $19.03B. The GAAP optics are genuinely ugly and will mislead a screen: diluted EPS just $2.36 (trailing PE 110x), book equity NEGATIVE -$3.27B (so PB and ROE are meaningless), driven by IPR&D write-offs and acquired-intangible amortization, not by the cash franchise. Forward PE is 15.8x, dividend is $6.92 forward (~3.1% yield, 66% payout on adjusted), beta 0.31 — a low-vol cash compounder hiding under accounting fog.

The thesis I flagged 06-08 was the classic dislocation: cash-flow yield the tape divorced from the franchise. The problem as of this meeting is that the dislocation closed before I could lead it — ABBV printed $227.23 on 2026-06-05, up ~6.7% in three sessions (217→225→227) off the early-June low. The 50-day MA is $208.81; the stock is now ~9% above it and back toward the upper half of its $176–$239 52-week range. The franchise re-rated; the "tape divorced from franchise" setup is gone at this level.

I will not chase. ABBV downgraded from likely-lead to a 3-conviction watch. The window I'd want is a pullback toward the $205–$210 area (the 50-day and the pre-rally base) on no fundamental news. Next earnings 2026-07-30, est EPS $3.77 (note: estimate is adjusted, vs the GAAP $2.36 trailing — exactly the optics gap that makes the name interesting). Health Care is underweight (9.3% fund vs 11% SPY), so the sector band is NOT a constraint here — unlike GIS/CVX, ABBV has band room; it's purely a price-discipline call.

How I'd know I'm wrong (to the downside, as a buyer): Skyrizi/Rinvoq combined run-rate stalling, or operating cash flow breaking below ~$16B — that would mean the post-Humira growth engines aren't covering the cliff and the 15.8x forward multiple is a value trap, not a discount.